Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-27

Study Completion Date

2024-11-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In part 1 NHVs will receive a single dose of ARO-MUC5AC or placebo. In part 2 of the study, NHVs, adult patients with asthma, and adult patients with COPD will receive 3 doses of ARO-MUC5AC or placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

NCT05537025

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE1/PHASE2

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

NCT05276570

Asthma

COMPLETED PHASE1/PHASE2

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805

Pulmonary/Respiratory Diseases

COMPLETED PHASE1

Nebulised BromAc in Healthy Volunteers

NCT05220605

COVID-19 Pneumonia Bromelains Adverse Reaction Acetylcysteine Adverse Reaction +2 more

COMPLETED PHASE1

Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD

NCT06841640

COPD

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ARO-MUC5AC

ARO-MUC5AC Inhalation

Group Type EXPERIMENTAL

ARO-MUC5AC

Intervention Type DRUG

single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution

Placebo

(0.9% NaCl)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

calculated volume to match active treatment by inhalation of nebulized solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ARO-MUC5AC

single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution

Intervention Type DRUG

Placebo

calculated volume to match active treatment by inhalation of nebulized solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal pulmonary function tests at Screening (NHVs only)
* Confirmed diagnosis of asthma or COPD based on source verifiable medical record (asthma and COPD patients only)
* No abnormal finding of clinical relevance at Screening (NHVs only)
* Stable dose of asthma controller medications for at least 28 days prior to Screening (asthma patients only)
* Documented treatment with an inhaled corticosteroid and at least 1 additional maintenance asthma controller medication for at least 3 months prior to Screening (asthma patients only)
* Non-smoking (NHVs and asthma patients)
* Current smoker or ex-smoker with smoking history of ≥ 10 pack-years (COPD patients only)
* All COPD treatments have been stable for at least one month prior to Screening (COPD patients only)
* Able to produce an induced sputum sample at Screening
* Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception. Males must not donate sperm during the study and for at least 90 days following the last dose of study drug
* Willing to provide written informed consent and to comply with study requirements

Exclusion Criteria

* Acute lower respiratory infection within 30 days prior to first dose and/or acute upper respiratory infection within 7 days prior to first dose
* Positive COVID-19 test during Screening window
* Any history of chronic pulmonary disease (NHVs only)
* Any concomitant pulmonary disease in asthma or COPD patients that could interfere with the evaluation of the study drug or interpretation of patient safety or study results
* Use of theophylline within 30 days prior to first dose
* History of lung volume reduction surgery or pneumonectomy (COPD patients)
* Need for chronic oxygen support at Screening
* Clinically significant health concerns (other than asthma in asthma patients)
* Human immunodeficiency virus (HIV) infection, seropositive for hepatitis B virus (HBV), seropositive for hepatitis C virus (HCV)
* Uncontrolled hypertension
* Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
* Use of illicit drugs
* Use of an investigational agent or device within 30 days prior to first dose

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes